Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa

Eur J Pharmacol. 2006 Nov 7;549(1-3):63-70. doi: 10.1016/j.ejphar.2006.08.013. Epub 2006 Aug 16.

Abstract

7-hydroxymitragynine, a constituent of the Thai herbal medicine Mitragyna speciosa, has been found to have a potent opioid antinociceptive effect. In the present study, we investigated the mechanism of antinociception and the inhibitory effect on gastrointestinal transit of 7-hydroxymitragynine, and compared its effects with those of morphine. When administered subcutaneously to mice, 7-hydroxymitragynine produced antinociceptive effects about 5.7 and 4.4 times more potent than those of morphine in the tail-flick (ED50=0.80 mg/kg) and hot-plate (ED50=0.93 mg/kg) tests, respectively. The antinociceptive effect of 7-hydroxymitragynine was significantly blocked by the mu1/mu2-opioid receptor antagonist beta-funaltrexamine hydrochloride (beta-FNA) and the mu1-opioid receptor-selective antagonist naloxonazine in both tests. Thus, 7-hydroxymitragynine acts predominantly on mu-opioid receptors, especially on mu1-opioid receptors. Isolated tissue studies further supported its specificity for the mu-opioid receptors. Further, 7-hydroxymintragynine dose-dependently (ED50=1.19 mg/kg, s.c.) and significantly inhibited gastrointestinal transit in mice, as morphine does. The inhibitory effect was significantly antagonized by beta-FNA pretreatment, but slightly antagonized by naloxonazine. The ED50 value of 7-hydroxymitragynine on gastrointestinal transit was larger than its antinociceptive ED50 value. On the other hand, morphine significantly inhibits gastrointestinal transit at a much smaller dose than its antinociceptive dose. These results suggest that mu-opioid receptor mechanisms mediate the antinociceptive effect and inhibition of gastrointestinal transit. This compound induced more potent antinociceptive effects and was less constipating than morphine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / chemistry
  • Analgesics / isolation & purification
  • Analgesics / pharmacology*
  • Analgesics, Opioid / pharmacology
  • Animals
  • Dose-Response Relationship, Drug
  • Gastrointestinal Transit / drug effects*
  • Gastrointestinal Transit / physiology
  • Guinea Pigs
  • Herbal Medicine
  • Ileum / drug effects
  • Ileum / physiology
  • Male
  • Mice
  • Mitragyna / chemistry*
  • Molecular Structure
  • Morphine / pharmacology
  • Muscle Contraction / drug effects
  • Naltrexone / analogs & derivatives
  • Naltrexone / pharmacology
  • Narcotic Antagonists / pharmacology
  • Narcotics / chemistry
  • Narcotics / isolation & purification
  • Narcotics / pharmacology
  • Pain / physiopathology
  • Pain / prevention & control
  • Pain Measurement / methods
  • Receptors, Opioid, mu / antagonists & inhibitors
  • Receptors, Opioid, mu / physiology*
  • Secologanin Tryptamine Alkaloids / chemistry
  • Secologanin Tryptamine Alkaloids / isolation & purification
  • Secologanin Tryptamine Alkaloids / pharmacology*
  • Thailand
  • Vas Deferens / drug effects
  • Vas Deferens / physiology

Substances

  • Analgesics
  • Analgesics, Opioid
  • Narcotic Antagonists
  • Narcotics
  • Receptors, Opioid, mu
  • Secologanin Tryptamine Alkaloids
  • 7-hydroxymitragynine
  • Naltrexone
  • beta-funaltrexamine
  • Morphine